Ganaxolone - Marinus Pharmaceuticals
Alternative Names: CCD-1042; Ganaxalone-IV; gnx; GNX oral suspension - Marinus Pharmaceuticals; ZTALMYLatest Information Update: 24 Oct 2024
At a glance
- Originator Purdue Pharma
- Developer Marinus Pharmaceuticals; Purdue Pharma; Tenacia Biotechnology
- Class Analgesics; Antidepressants; Antiepileptic drugs; Antimigraines; Anxiolytics; Ketones; Neuroprotectants; Pregnanes; Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Early infantile epileptic encephalopathy 2
- Phase III Status epilepticus; Tuberous sclerosis
- Phase II Epilepsy; Fragile X syndrome
- Phase I Lennox-Gastaut syndrome
- Suspended Major depressive disorder; Postnatal depression
- No development reported Angelman syndrome
- Discontinued Infantile spasms; Migraine; Neuropathic pain; Partial epilepsies; Post-traumatic stress disorders
Most Recent Events
- 17 Oct 2024 Efficacy data from a phase III trial in Status Epilepticus released by Marinus Pharmaceuticals
- 15 Oct 2024 Marinus Pharmaceuticals has patent protection for Ganaxolone in US
- 22 Sep 2024 Updated efficacy and adverse events data from the phase II TSC trial in Tuberous sclerosis released by Marinus Pharmaceuticals